NO-donors, part X[1]: Investigations on the stability of pentaerythrityl tetranitrate (PETN) by HPLC-chemoluminescence-N-detection (CLND) versus UV-detection in HPLC

Journal of Pharmaceutical and Biomedical Analysis

Volumn 40, Issue 5, 2006, Pages 1131-1136

  Seeling, Andreas ^a   Lehmann, Jochen ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

CLND; HPLC; N Selective detection; Organonitrate; PETN; Stability; Thioles

Indexed keywords

BUFFER; CYSTEINE; NITRIC OXIDE DONOR; PENTAERYTHRITYL TETRANITRATE; THIOGLYCOLIC ACID; THIOPHENE;

ARTICLE; CHEMOLUMINESCENCE; DEGRADATION; DEGRADATION KINETICS; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; INTESTINE FLUID; PLASMA; PRIORITY JOURNAL; STOMACH JUICE; ULTRAVIOLET RADIATION;

CHEMILUMINESCENT MEASUREMENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HYDROLYSIS; NITRIC OXIDE DONORS; OXIDATION-REDUCTION; PENTAERYTHRITOL TETRANITRATE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLUTIONS; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 32644480661     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2005.09.007     Document Type: Article

References (22)

1. G.E.D.A.A. Abuo-Rahma, A. Horstmann, M.F. Radwan, A. El-Emam, E. Glusa, and J. Lehmann Eur. J. Med. Chem. 40 2005 281 287 (Part 9)
2. B. Fink, and B.E. Bassenge J. Cardiovasc. Pharmacol. 30 1997 831 836
3. U. Jurt, T. Gori, A. Ravandi, S. Babaei, P. Zeman, and J.D. Parker J. Am. Coll. Cardiol. 38 2001 854 859
4. U. Hess, H. Brösig, G. König, and M. Stoeter E. Mutschler D. Schneider D. Stalleicken Pentaerythrityltetranitrat: NO-substitution als pharmakologisch begründetes Therapieprinzip 2000 Steinkopff-Verlag Darmstadt 18 26
5. Z. Chen, and J.S. Stamler Proc. Natl. Acad. Sci. U.S.A. 99 2002 8306 8311
6. W. Weber, K. Michaelis, V. Luckow, U. Kuntze, and D. Stalleicken Arzneim.-Forsch./Drug Res. 45 1995 781 784
7. D. Stalleicken, U. Kuntze, B. Schmid, R. Hiebl, J. Ring, and K. Michaelis Arzneim.-Forsch./Drug Res. 47 1997 347 352
8. A. Schutz, J. Kotting, F. Epple, R. Ziegler, H. Maier-Lenz, and D. Stalleicken Arzneim.-Forsch./Drug Res. 49 1999 891 895
9. I.W.F. Davidson, F.J. DiCarlo, and E.I. Szabo J. Chromatogr. 57 1971 345 352
10. W.C. Yu, E.U. Goff, and D.H. Fine Proc. Int. Symp. Anal. Detect. Explos. 1983 329 340
11. W.C. Yu, and E.U. Goff Biopharm. Drug Dispos. 4 1983 311 319
12. The United States Pharmacopeia 26th ed. 2003 The United States Pharmacopeial Convention Inc. Rockville, MD
13. European Pharmacopoeia 4th ed. 2002 Deutscher-Apotheker-Verlag Stuttgart
14. J.B.F. Lloyd J. Chromatogr. 257 1983 123 127
15. C.E. Parker J. Foren. Sci. 27 1982 495-450
16. S. Dikalov, B. Fink, M. Skatchkov, D. Stalleicken, and E. Bassenge J. Pharmacol. Exp. Ther. 286 1998 938 944
17. R. Radi, J.S. Beckman, K.M. Bush, and B.A. Freeman J. Biol. Chem. 266 1991 4244 4250
18. T. Gori, and A. Al-Hesayen Am. J. Cardiol. 91 2003 1392 1394
19. S. Dikalov, B. Fink, M. Skatchov, and E. Bassenge Free Rad. Biol. Med. 27 1999 170 176
20. P. Needleman, and E.M. Johnson J. Pharmacol. Exp. Ther. 184 1997 709 715
21. D. Stalleicken Pentaerythrityltetranitrat: Therapierelevanter Wissensstand zu Pharmakologie und Klinik 2004 Steinkopff-Verlag Darmstadt 43 45
22. U. Hess, H. Brosig, G. Konig, M. Stoeter, and D. Stalleicken Pharmazie 57 2002 460 464